AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34401600
Drug: BLZ-100 (tozuleristide)
RxNorm normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLZ-100 (tozuleristide) administered intravenously at doses of 1, 3, 6, 12, and 18 mg, 2 days before tumor excision.
Trial: 34401600
Drug: BLZ-100 (tozuleristide)
RxNorm normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLZ-100 (tozuleristide) administered intravenously at intermediate doses (3-12 mg).
Trial: 34401600
Drug: BLZ-100 (tozuleristide)
RxNorm normalized name: BLZ-945
DrugBank: BLZ-945 (DB16838)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLZ-100 (tozuleristide) administered intravenously.
Trial: 34401861
Drug: Atorvastatin-based lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin-based lipid therapies and lifestyle intervention for 2 years
Trial: 34403125
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for chronic pain and shared decision-making for prescription opioid dose reduction
Trial: 34404358
Drug: Curcumin 1500
RxNorm normalized name: Nature's Truth Turmeric Curcumin 1500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 1500 mg by mouth twice daily for 12 weeks
Trial: 34404463
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Trial: 34404463
Drug: Placebo subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Trial: 34404711
Drug: Acute kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute kidney replacement therapy (KRT)
Trial: 34404711
Drug: Driving safety,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Driving safety, adverse events, and medication adherence assessment
Trial: 34405140
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of CD45RA memory T cells
Trial: 34405577
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) at doses of 35 Gy, 37.5 Gy, 40 Gy, 42.5 Gy, and 45 Gy in five fractions
Trial: 34406502
Drug: Topical low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical low-dose (1,005 mg) preservative-free hydrocortisone, administered twice daily in each eye for 2 weeks.
Trial: 34407260
Drug: 4 mm
RxNorm normalized name: potassium 8.4 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mm pen needles combined with education on injection technique
Trial: 34407735
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inotuzumab ozogamicin in combination with temsirolimus
Trial: 34407844
Drug: M2698 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2698 monotherapy (15-380 mg daily)
Trial: 34407844
Drug: M2698/trastuzumab (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2698/trastuzumab (160 mg QD)
Trial: 34407844
Drug: M2698/tamoxifen (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M2698/tamoxifen (160 mg QD/240 mg intermittent regimen)
Trial: 34407972
Drug: MTL-CEBPA combined
RxNorm normalized name: Allium cepa bulb extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTL-CEBPA combined with checkpoint inhibitors or PMN-MDSC-targeted immunotherapy
Trial: 34408049
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide fumarate (TAF) monotherapy
Trial: 34408750
Drug: 6B11-OCIK adoptive
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6B11-OCIK adoptive cell therapy (autologous T cells induced by 6B11 minibody plus dendritic cells and cytokines)
Trial: 34409288
Drug: 1MIU low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1MIU low-dose interleukin-2
Trial: 34409288
Drug: 2MIU low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2MIU low-dose interleukin-2
Trial: 34409593
Drug: ACEI or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI or ARBs treatment
Trial: 34409593
Drug: No ACEI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ACEI or ARBs treatment
Trial: 34409593
Drug: ACEI or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI or ARBs treatment at discharge
Trial: 34409593
Drug: Antiviral drugs,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drugs, interferon treatment, oral anticoagulation at discharge
Trial: 34411009
Drug: Intranasal esketamine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal esketamine
Trial: 34411009
Drug: Intravenous racemic
RxNorm normalized name: EPINEPHRINE,RACEMIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous racemic ketamine
Trial: 34412682
Drug: Camostat tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat tablets, 200 mg four times daily (qds) for 14 days
Trial: 34412687
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol for 6 months
Trial: 34413106
Drug: Web-based self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based self-administered health-related data collection system
Trial: 34413166
Drug: Cemiplimab 3
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 3 mg/kg every 2 weeks (group 1, mCSCC)
Trial: 34413166
Drug: Cemiplimab 3
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 3 mg/kg every 2 weeks (group 2, locally advanced CSCC)
Trial: 34413166
Drug: Cemiplimab 350
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cemiplimab 350 mg every 3 weeks (group 3, mCSCC)
Trial: 34413210
Drug: High-dose inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose inhaled nitric oxide (INO) at 160 ppm for 15 min twice daily
Trial: 34413210
Drug: Electric NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electric NO (eNO) generator at 160 ppm for 15 min twice daily
Trial: 34413210
Drug: Pressurized nitrogen/NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized nitrogen/NO cylinders (INO) at 160 ppm for 15 min twice daily
Trial: 34413249
Drug: Respiratory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respiratory treatment
Trial: 34413249
Drug: Factors associated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factors associated with respiratory treatment
Trial: 34414532
Drug: Ribociclib 600
RxNorm normalized name: letrozole 2.5 MG / ribociclib 600 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 600 mg/day (3-weeks-on/1-week-off) plus letrozole 2.5 mg/day and monthly goserelin/leuprolide in men and pre-/perimenopausal women
Trial: 34414986
Drug: Immunological studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunological studies (in vitro stimulation with toll-like receptor ligands)
Trial: 34415049
Drug: Seasonal influenza
RxNorm normalized name: seasonal influenza, intradermal, preservative free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal influenza vaccination (2 doses for HSCT patients)
Trial: 34415114
Drug: MINT therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MINT therapy (wearable myoelectric interface)
Trial: 34415964
Drug: Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1 (received standard dose)
Trial: 34415964
Drug: Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 (received higher first dose and fractional fifth dose)
Trial: 34415964
Drug: Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2 (fractional fifth dose)
Trial: 34416160
Drug: Antiangiogenic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiangiogenic agents combined with systemic chemotherapy
Trial: 34416167
Drug: PD-1/L1 therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/L1 therapy followed by MAPK inhibitors (MAPKi)
Trial: 34416167
Drug: MAPK inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAPK inhibitors (MAPKi)
Trial: 34416175
Drug: Oral tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tenofovir disoproxil fumarate (300 mg/day) initiated between 28-32 weeks of gestation and continued through 12 weeks postpartum.
Trial: 34416175
Drug: Birth-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth-dose of monovalent HBV vaccine (Euvax-B Pediatric: 0.5 mL) administered within 24 hours of life.
Trial: 34416175
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment or vaccination (control group not explicitly mentioned).
Trial: 34416758
Drug: Pharmacotherapy (specifics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (specifics not provided)
Trial: 34417144
Drug: Trametinib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib 1.5 mg oral daily and panitumumab 4.8 mg/kg IV every 2 weeks
Trial: 34417162
Drug: PNT2258 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNT2258 120 mg/m intravenously
Trial: 34417212
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GST-π and PRDX1
Trial: 34417444
Drug: Obinutuzumab-atezolizumab-lenalidomide (G-atezo-len)
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab-atezolizumab-lenalidomide (G-atezo-len)
Trial: 34417675
Drug: Veliparib 30
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib 30 to 40 mg twice daily on days 1 to 7 with concurrent temozolomide 150 mg/m²
Trial: 34417919
Drug: Lactate concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate concentration ≥ 2.0 mmol/L on the day of ICU admission (baseline)
Trial: 34418086
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray (Valtoco) administered 4390 times for 3853 seizure clusters
Trial: 34418086
Drug: Diazepam nasal
RxNorm normalized name: diazepam Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam nasal spray (Valtoco)
Trial: 34419010
Drug: Enhanced usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced usual care (EUC) including depression treatment according to clinical guidelines and usual medical care for chronic diseases
Trial: 34419752
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) for depression; 20 individual sessions over 16 weeks
Trial: 34420548
Drug: 4000 L
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 L production-scale alglucosidase alfa
Trial: 34421148
Drug: Subanesthetic intravenous
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic intravenous ketamine
Trial: 34421925
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone pulse therapy (IVMP) alone
Trial: 34421925
Drug: IVMP combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVMP combined with intravenous immunoglobulin
Trial: 34423319
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for ARFID (CBT-AR), 20-30 outpatient sessions delivered by therapists.
Trial: 34424319
Drug: LCL161 (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCL161 (oral, starting dose, 1500 mg per week)
Trial: 34424546
Drug: Standard-dose rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose rhGH (approximately 0.3 mg/kg/week)
Trial: 34424546
Drug: High-dose rhGH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rhGH (0.5 mg/kg/week)
Trial: 34424934
Drug: Supplement (2g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (2g fish oil with 1500 IU vitamin D3 1x/d + 20-30g whey protein powder with 3g leucine 2x/d)
Trial: 34425261
Drug: High-dose post-transplantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose post-transplantation cyclophosphamide (PTCy)
Trial: 34425406
Drug: Palbociclib plus
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palbociclib plus endocrine therapy (exemestane or fulvestrant)
Trial: 34425763
Drug: Interferon beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon beta-1b (IFNB-1b) treatment started within 6 months before study entry.
Trial: 34425825
Drug: Self-reported oral
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported oral health
Trial: 34425825
Drug: Children's oral
RxNorm normalized name: Maalox Children's Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children's oral health related quality of life
Trial: 34425850
Drug: YY-20394 (20-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YY-20394 (20-200 mg daily)
Trial: 34425850
Drug: YY-20394 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YY-20394 (40 mg q.d.)
Trial: 34425850
Drug: YY-20394 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YY-20394 (80 mg q.d.)
Trial: 34426012
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs)
Trial: 34426012
Drug: Glucagon-like peptide
RxNorm normalized name: Glucagon-like peptide 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon-like peptide 1 receptor agonists (GLP-1RAs)
Trial: 35441935
Drug: Steroidal mineralocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroidal mineralocorticoid receptor antagonists (MRAs)
Trial: 34426402
Drug: Subconjunctival dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subconjunctival dexamethasone implant injected at the end of PK
Trial: 34426402
Drug: Subconjunctival dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subconjunctival dexamethasone implant
Trial: 34426402
Drug: Steroid eye-drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid eye-drop treatment planned after implant resorption
Trial: 34426443
Drug: Telisotuzumab vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telisotuzumab vedotin (Teliso-V) monotherapy at a dose of 1.9 mg/kg once every 2 weeks
Trial: 34426443
Drug: Telisotuzumab vedotin
RxNorm normalized name: Telisotuzumab vedotin
DrugBank: Telisotuzumab vedotin (DB15104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telisotuzumab vedotin (Teliso-V) monotherapy at a dose of 2.7 mg/kg once every 3 weeks
Trial: 34427465
Drug: Standard NAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard NAC with or without experimental agents
Trial: 34427788
Drug: Medial to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial to lateral (ML) dissection
Trial: 34427788
Drug: ML group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML group
Trial: 34427990
Drug: Enasidenib 100
RxNorm normalized name: enasidenib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib 100 mg daily
Trial: 34428076
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with gemcitabine and cisplatin plus pembrolizumab
Trial: 34428285
Drug: CC-486 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-486 (oral azacitidine) plus R-CHOP
Trial: 34428992
Drug: rituximab monotherapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab monotherapy (R-mono)
Trial: 34429088
Drug: Development of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development of diet- and microbe-based therapies
Trial: 34429090
Drug: G-YSQ (German
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-YSQ (German version of the Young Spine Questionnaire)
Trial: 34429090
Drug: G-YSQ
RxNorm normalized name: Glyburide-Metformin
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-YSQ
Trial: 34429332
Drug: Durvalumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab plus tremelimumab (tremelimumab 75 mg plus durvalumab 1500 mg once every 28 days for four cycles, then durvalumab alone every 28 days until disease progression)
Trial: 34430604
Drug: IV Treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV Treprostinil (TRE) at an initial rate of 5 ng/kg/min, increased to 10 ng/kg/min every 30 min until reaching 80 ng/kg/min, administered for 12 hours.
Trial: 34430790
Drug: Marzeptacog alfa
RxNorm normalized name: Marzeptacog alfa (activated)
DrugBank: Marzeptacog alfa (activated) (DB15278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marzeptacog alfa (activated) (MarzAA) 30 μg/kg SC daily for 50 days
Trial: 34432206
Drug: Jianpi Bushen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi Bushen Sequential Formula (JBSF)
Trial: 34432679
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INR/(CHE*platelet count)
Trial: 34432679
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MELD/(CHE*platelet count)
Trial: 34433303
Drug: UGN-102 (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 (6 once-weekly instillations)
Trial: 34433549
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex)
Trial: 34433593
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural treatment for childhood insomnia (CBT-CI) adapted for children with ASD (in-person or remote)
Trial: 34433608
Drug: 12-month dietary
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month dietary intervention delivered via face-to-face motivational interviews, fortnightly motivational phone calls, monthly electronic pamphlets, quarterly newsletters and quarterly group meetings.
Trial: 34433649
Drug: Lenalidomide Monotherapy
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide Monotherapy
Trial: 34435395
Drug: BEO (bergamot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEO (bergamot essential oil) cream (80 mg) applied trans-dermally twice a day for 4 weeks
Trial: 34435395
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied trans-dermally twice a day for 4 weeks
Trial: 34435552
Drug: Early PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early PET/CT scans on days 4 (D4) and 21 (D21) of cycle 1 (C1) of salvage therapy
Trial: 34435897
Drug: Medical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatments affecting bone metabolism
Trial: 34436569
Drug: ABX464 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 (150 mg daily for 4 weeks)
Trial: 34439146
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiation therapy (SBRT) delivered as planned (60Gy in 15 fractions of 4.0Gy)
Trial: 34439167
Drug: Fasting-Mimicking Diet
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting-Mimicking Diet (FMD) administered every three weeks/once a month, average of 6.3 cycles/patient
Trial: 34439284
Drug: zPDX (zebrafish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zPDX (zebrafish patient-derived xenograft) exposed to chemotherapy regimens
Trial: 34439518
Drug: Deferoxamine (DFO)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine (DFO) 40-60 mg/Kg/day